Home » Stocks » HALO

Halozyme Therapeutics, Inc. (HALO)

Stock Price: $48.84 USD 0.04 (0.08%)
Updated Jan 26, 2021 10:37 AM EST - Market open
Market Cap 6.47B
Revenue (ttm) 199.56M
Net Income (ttm) 21.52M
Shares Out 136.58M
EPS (ttm) 0.15
PE Ratio 317.14
Forward PE 32.68
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $48.84
Previous Close $48.80
Change ($) 0.04
Change (%) 0.08%
Day's Open 49.11
Day's Range 48.29 - 49.69
Day's Volume 207,034
52-Week Range 13.90 - 49.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

SAN DIEGO, Jan. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) has received U.S. Food and Drug Administration (FDA) ap...

Zacks Investment Research - 1 week ago

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

Other stocks mentioned: BPMC, NVAX
Zacks Investment Research - 2 weeks ago

We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.

Other stocks mentioned: BPMC, MRNA
PRNewsWire - 1 month ago

SAN DIEGO, Dec. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission has approved Roche's Phesgo®, a fixed-dose combination of Perje...

Zacks Investment Research - 1 month ago

The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U...

Other stocks mentioned: BCRX, QDEL, TDOC, XLRN
Zacks Investment Research - 1 month ago

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Seeking Alpha - 1 month ago

Halozyme has settled into its role as a royalty cash machine after transitioning away from a drug discovery company, and the immediate future looks very bright. With 5 products currently on th...

Zacks Investment Research - 1 month ago

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 month ago

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 2 months ago

Horizon (HZNP) inks deal to get an exclusive access to Halozyme's ENHANZE drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R.

PRNewsWire - 2 months ago

SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration...

Business Wire - 2 months ago

DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gi...

Other stocks mentioned: HZNP
PRNewsWire - 2 months ago

SAN DIEGO, Nov. 18, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in a fireside...

PRNewsWire - 2 months ago

SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (C...

PRNewsWire - 2 months ago

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Janssen Pharmaceutical Companies submitted regulatory applications to the U.S. Food...

PRNewsWire - 2 months ago

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that studies sponsored by Janssen Research & Development, LLC (Janssen) evaluating subcutaneo...

Schaeffers Research - 2 months ago

The shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)  are up 3.6% to trade at $32.77 at last check, after earlier hitting an all-time high of $33.23.

Investors Business Daily - 2 months ago

Halozyme Therapeutics boosted its EPS and sales guidance for the year, buoyed by partnerships with big drugmakers such as Roche and Johnson & Johnson, sparking HALO stock to a record high. The...

Zacks Investment Research - 2 months ago

Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.

Seeking Alpha - 2 months ago

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 2 months ago

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 25.00% and 8.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...

Zacks Investment Research - 2 months ago

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 3 months ago

SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme and argenx are expanding their existing global collaboration and license agreem...

PRNewsWire - 4 months ago

SAN DIEGO, Sept. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Zacks Investment Research - 4 months ago

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 4 months ago

SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Zacks Investment Research - 5 months ago

Halozyme (HALO) reports lower-than-expected Q2 earnings. Shares down.

Seeking Alpha - 5 months ago

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -24.00% and -20.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for th...

PRNewsWire - 5 months ago

SAN DIEGO, Aug. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Zacks Investment Research - 5 months ago

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

Other stocks mentioned: FOLD, ICPT, NVAX, RETA
PRNewsWire - 5 months ago

SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Zacks Investment Research - 5 months ago

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 6 months ago

Halozyme Therapeutics: Enhanced Prospects, Expensive Valuations

Forbes - 6 months ago

A bull signal is flashing for Halozyme Therapeutics (HALO), which just came off a record peak

PRNewsWire - 6 months ago

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab, t...

Zacks Investment Research - 7 months ago

Halozyme Therapeutics (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

PRNewsWire - 7 months ago

SAN DIEGO, June 17, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the u...

PRNewsWire - 7 months ago

SAN DIEGO, June 13, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Research & Development, LLC (Janssen) presented data from its Phase III ANDROME...

Zacks Investment Research - 7 months ago

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 7 months ago

SAN DIEGO, June 4, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted Janssen-Cilag International NV (Janssen) market...

PRNewsWire - 7 months ago

SAN DIEGO, May 28, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the fo...

Zacks Investment Research - 8 months ago

Halozyme (HALO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Investment Research - 8 months ago

Halozyme (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Top Ranked Momentum Stocks to Buy for May 15th

Other stocks mentioned: IIVI, KOPN, MEIP
PRNewsWire - 8 months ago

SAN DIEGO, May, 14, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $15 million milestone payment from Janssen Biotech, Inc. (Janssen...

Zacks Investment Research - 8 months ago

Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.

Seeking Alpha - 8 months ago

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -300.00% and -35.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for ...

About HALO

Halozyme Therapeutics operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administr... [Read more...]

Industry
Biotechnology
Founded
1998
CEO
Helen Torley
Employees
132
Stock Exchange
NASDAQ
Ticker Symbol
HALO
Full Company Profile

Financial Performance

In 2019, HALO's revenue was $195.99 million, an increase of 29.06% compared to the previous year's $151.86 million. Losses were -$72.24 million, -10.07% less than in 2018.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is 44.00, which is a decrease of -9.91% from the latest price.

Price Target
$44.00
(-9.91% downside)
Analyst Consensus: Buy